Prophylaxis against recurrent hepatitis B virus infection after liver transplantation

被引：0
作者：
Curry M.P. [1 ]
Afdhal N.H. [1 ]
机构：
[1] Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215
来源：
Current Hepatitis Reports | 2007年 / 6卷 / 1期
关键词：
Lamivudine; Adefovir; Entecavir; Adefovir Dipivoxil; Lamivudine Monotherapy;
D O I：
10.1007/BF02942176
中图分类号：
学科分类号：
摘要：
Over the past two decades, there have been significant improvements in the outcomes of liver transplantation for all indications. Liver transplantation for hepatitis B virus (HBV) infection, once considered a contraindication to transplantation, now achieves survival rates of 91% at 1 year, 81% at 5 years, and 73% at 10 years. This improvement in outcome has occurred largely with the introduction of therapies that prevent reinfection of the hepatic allograft and thus recurrent hepatitis B, cirrhosis, and graft failure. In the United States, it is estimated that 1.25 million people are chronically infected with HBV, resulting in approximately 5000 liver-related deaths and 250 liver transplantations annually. This review summarizes the important accomplishments in the successful application of liver transplantation for liver disease related to HBV infection. Copyright © 2007 by Current Medicine Group LLC.
引用
收藏
页码：30 / 34
页数：4
相关论文
共 38 条
  • [1] O'Grady J.G., Williams R., Liver transplantation for viral hepatitis, Br Med Bull, 46, pp. 481-491, (1990)
  • [2] Hart J., Busuttil R.W., Lewin K.J., Disease recurrence following liver transplantation, Am J Surg Pathol, 14, SUPPL. 1, pp. 79-91, (1990)
  • [3] Demetris A.J., Todo S., Van Thiel D.H., Et al., Evolution of hepatitis B virus liver disease after hepatic replacement. Practical and theoretical considerations, Am J Pathol, 137, pp. 667-676, (1990)
  • [4] Belle S., Beringer K., Murphy J., Detre K., The Pitt-UNOS Transplant Registry, Clinical Transplants, pp. 17-32, (1992)
  • [5] Charlton M., Seaberg E., Wiesner R., Et al., Predictors of patient and graft survival following liver transplantation for hepatitis C, Hepatology, 28, pp. 823-830, (1998)
  • [6] Kim W.R., Poterucha J.J., Kremers W.K., Et al., Outcome of liver transplantation for hepatitis B in the United States, Liver Transpl, 10, pp. 968-974, (2004)
  • [7] Samuel D., Muller R., Alexander G., Et al., Liver transplantation in European patients with the hepatitis B surface antigen, N Engl J Med, 329, pp. 1842-1847, (1993)
  • [8] Roche B., Feray C., Gigou M., Et al., HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis, Hepatology, 38, pp. 86-95, (2003)
  • [9] Sawyer R.G., McGory R.W., Gaffey M.J., Et al., Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization, Ann Surg, 227, pp. 841-850, (1998)
  • [10] Yoshida E.M., Erb S.R., Partovi N., Et al., Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin, Liver Transpl Surg, 5, pp. 520-525, (1999)
1234